Close Menu

HER2 Biomarkers

News and reporting on HER2 biomarkers.

NICE's recommendation for NHS to pay for AstraZeneca's non-small cell lung cancer drug Iressa in EGFR mutation-positive patients marks the second personalized medicine product to be funded in the UK after Herceptin was approved in 2002 for HER2-overexpressing breast cancer patients.

Hal Barron, Genentech's chief medical officer, said that "by using [Dako's] diagnostics to help identify the right patients" who will benefit from treatment, Genentech hopes to make Herceptin "the first targeted option for advanced HER2-positive stomach cancer."

CAP and ASCO issued new guidelines to improve accuracy of immunohistochemistry-based ER and PgR testing in breast cancer. The groups estimate that between 10 percent and 20 percent of IHC test results throughout the world may be inaccurate, yielding false-positive or false-negative results.

In the retrospective meta-analysis presented at the European Breast Cancer Conference this week, around 67 percent of patients with CEP17 tumors treated with anthracyclines experienced recurrence-free survival and overall survival in this group was 63 percent.

Genomic Health has been conducting a number of studies to examine how well its RT-PCR-based Oncotype DX test compares to IHC and FISH for assessing the HER2 status of breast cancer patients.

Pages

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.